The AAD/NPF guidelines define mild psoriasis as <3% BSA and moderate ... often come into play when deciding how to start psoriasis treatment. "I usually start with topical steroids," he said.

Less than a quarter of patients diagnosed with mild psoriasis had a body surface area of less than 3% at the time of diagnosis.

SFA Therapeutics, Inc. has announced encouraging results from its Phase 1b clinical trial of SFA-002, an oral drug candidate aimed at treating mild-to-moderate psoriasis. The study demonstrated both ...

Announcing a new publication for Acta Materia Medica journal. Phosphodiesterase-4 (PDE4), a member of the phosphodiesterase ...

talk with your doctor about coping tips or other treatment options. Sotyktu comes as an oral tablet and is used in adults to treat plaque psoriasis. Keep reading to learn about the common, mild ...

Under the NPF classification, psoriasis is considered mild when lesions cover less than 2% of the body surface area (typically on the knees, elbows, scalp, hands, and feet). Topical treatments ...

LEO Pharma and Reig Jofre have entered into a partnership aimed at improving access to LEO’s psoriasis treatment in Europe.

"Our tailored approach to immune regulation holds promise in providing a safer, more efficacious oral treatment for patients suffering from psoriasis." "Mild-to-moderate patients represent over 80 ...

Spain-based drugmaker REIG JOFRE has signed a commercial agreement with LEO Pharma, a privately-held Danish firm specializing ...

All treatment emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs) and were mild or moderate. Psoriasis is a chronic, recurrent, inflammatory, and immune-mediated systemic ...